Burgenske, Danielle M.
Mayo Clinic · Mayo Clinic Comprehensive Cancer Center (Minnesota)
4 papers on CoChatORCID 0000-0003-0014-5579
Most cited papers
- Verified
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma
Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics
Glioma Diagnosis and TreatmentCancer-related Molecular Pathways
Cited by 8
- Verified
Abstract 3870: The addition of CB-839 to temozolomide significantly reduces glioma aspartate and glutamate in an IDH mutated patient derived glioma xenograft model
Kizilbash, S. H., Burgenske, D. M., McBrayer, S., Devarajan, S., Gupta, S. K., Hitosugi, T., He, L., Schroeder, M. A., Carlson, B. L., Gelman, M., et al. (2019) · Cancer Research
Glioma Diagnosis and TreatmentCancer, Hypoxia, and Metabolism
Cited by 4
- Verified
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma
Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research
Glioma Diagnosis and TreatmentCancer-related Molecular Pathways
Cited by 2
- Verified
Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts
Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances
Glioma Diagnosis and TreatmentCancer-related Molecular Pathways
Cited by 0
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free